Short Interest in Bavarian Nordic (OTCMKTS:BVNRY) Decreases By 79.8%

Bavarian Nordic (OTCMKTS:BVNRY) saw a large decline in short interest in the month of June. As of June 15th, there was short interest totaling 2,985 shares, a decline of 79.8% from the May 31st total of 14,745 shares. Based on an average trading volume of 4,713 shares, the days-to-cover ratio is presently 0.6 days. Approximately 0.0% of the shares of the company are sold short.

Bavarian Nordic Trading Up 0.5%

BVNRY opened at $9.05 on Friday. The stock’s fifty day simple moving average is $9.67 and its 200 day simple moving average is $9.89. Bavarian Nordic has a 1-year low of $8.67 and a 1-year high of $13.00. The stock has a market cap of $2.15 billion, a PE ratio of 11.91 and a beta of 1.19.

Bavarian Nordic (OTCMKTS:BVNRY) last released its quarterly earnings data on Wednesday, May 13th. The company reported $0.01 EPS for the quarter. Bavarian Nordic had a net margin of 19.74% and a return on equity of 9.32%. The firm had revenue of $165.70 million during the quarter.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.